eXoZymes Inc. (EXOZ)
NASDAQ: EXOZ
· Real-Time Price · USD
9.70
-0.29 (-2.90%)
At close: Aug 15, 2025, 3:49 PM
10.01
3.20%
After-hours: Aug 15, 2025, 04:04 PM EDT
Company Description
eXoZymes, Inc. operates as a synthetic biochemical company in the United States.
The company develops SimplePath, a platform that produces chemicals, including pharmaceuticals, fuels, materials, food additives, and novel compounds.
Its platform also comprises one or more module which consist of one or more enzymes that work together to perform a defined biocatalytic conversion.
The company was founded in 2014 and is headquartered in Monrovia, California.
eXoZymes Inc.
| Country | United States |
| IPO Date | Nov 13, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 31 |
| CEO | Michael Heltzen |
Contact Details
Address: 750 Royal Oaks Drive Monrovia, Nevada United States | |
| Website | https://exozymes.com |
Stock Details
| Ticker Symbol | EXOZ |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0002010788 |
| CUSIP Number | n/a |
| ISIN Number | US4618741098 |
| Employer ID | 83-4550057 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Michael Heltzen | President & Chief Executive Officer |
| Damien A. Perriman | Chief Commercial Officer |
| Dr. Paul Opgenorth Ph.D. | Co-Founder & Vice President of Development |
| Dr. Tyler Korman Ph.D. | Co-Founder & Vice President of Research |
| Dr. Zachary Karl Ph.D. | Vice President & Head of Business Development |
| Fouad Nawaz | Vice President of Finance |
| James U. Bowie Ph.D. | Founder & Independent Director |
| Lasse H. Gorlitz | Vice President of Communications |
| Michael Burns | Executive Vice President of Energy Transition |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 12, 2025 | 10-Q | Quarterly Report |
| Jul 08, 2025 | 424B3 | Filing |
| Jul 08, 2025 | 8-K | Current Report |
| Jul 02, 2025 | 4 | Filing |
| Jun 26, 2025 | 8-K | Current Report |
| Jun 23, 2025 | DEFR14A | Filing |
| Jun 20, 2025 | DEF 14A | Filing |
| Jun 20, 2025 | 8-K | Current Report |
| Jun 20, 2025 | 4 | Filing |
| Jun 17, 2025 | 4 | Filing |